Tech Company Financing Transactions
Infinitopes Funding Round
Octopus Ventures, Cancer Research Institute and Kindred Capital participated in a $16 million Seed funding round for Infinitopes. The funding round closed on 5/1/2024.
Transaction Overview
Company Name
Announced On
5/1/2024
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the installation of LC-MS/MS mass spectrometer equipment, enhancing it proprietary tumour antigen discovery and computational immunobiology/AI/machine learning techniques, to identify and rank the best target combinations, to treat five more cancers.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
BioEscalator Innovation Building, Oxford University, 696 Roo
Headington, Oxford, OX3 7FZ
UK
Headington, Oxford, OX3 7FZ
UK
Phone
Website
Email Address
Overview
Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jonathan Kwok
Chief Scientific Officer
Paul Klenerman
Vice President
Senthil Channakannan
Vice President
Lian Lee
Browse more venture capital transactions:
Prev: 5/1/2024: CoreWeave venture capital transaction
Next: 5/1/2024: RunReveal venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs